鹍 Yuan gene completed 1 billion yuan financing to set a record for the highest early screening of cancer in China

Medical Valley recently learned that the gene sequencing service providerYuan Gene, located in Zhangjiang Science City Shanghai International Medical Park, announced the completion of nearly 1 billion yuan B round of financing, led by THEC Kaide Innovative Biopharmaceutical Fund under THEC Capital, Detong Capital, Complex Investment Leading investment, Huamei International, Channel Capital, Wuxi Gold Investment, FutureX Sky capital, Shanghai Free Trade Zone Fund and other well-known venture capital institutions and industrial funds with investment, old shareholders Songyu Capital, Jingxu Venture Capital, next to the star venture capital this round continue to follow investment.
, this is also the highest amount of corporate financing in the field of early screening of cancer in China.
it is understood that this round of financing is mainly used to expand the company's cancer early screening product research and development pipeline, and will focus on promoting the registration of products and commercialization process, as well as pan-cancer early screening products to expand forward-looking verification.
Prior to this,Yuangen has completed two rounds of financing, in August 2016 to obtain Lilly Asia Fund led by 120 million yuan A round of financing, in February 2018 to obtain Songyu Capital and Jingxu Ventures, Pioneer Medical Investment, Kyusju Tong Pharmaceutical Group, Lilly Asia Fund and other new and old investors with the investment of 60 million U.S. dollars of A-round financing.
public information shows thatFar Gene was established in 2014, mainly around the prevention, occurrence and development of tumors, the development of high incidence of cancer risk assessment, early screening, drug guidance and postoperative monitoring of a series of solutions, especially based on the patented methylation detection platform of tumor non-invasive early screening and diagnostic technology development and application, product line covering lung cancer, colorectal cancer, liver cancer, stomach cancer, esophageal cancer, pancreatic cancer, thyroid cancer and many other cancers.
At this year's annual meeting of the European Society of Oncology (ESMO),far gene based on the patented ctDNA methylation testing technology, in the form of poster published with a number of domestic triplet hospitals and well-known expert doctors in cooperation with the latest research results of three cancer early screening, specifically related to lung cancer, thyroid cancer, pancreatic cancer and many other common cancers in China early screening clinical research.
Taking lung cancer as an example,Far Gene, in collaboration with Huaxi Hospital of Sichuan University and Fudan University Affiliated Oncology Hospital, developed Luna analysis method based on ctDNA methylated liquid biopsy, which can accurately distinguish benign lung nods and lung cancer (especially early lung cancer) from tissue samples.
studies have shown that DNA methylation markers contained in Luna panel can accurately distinguish between lung adenocarcinoma patients and healthy subjects through plasma samples.
In addition, the study also found that Luna analysis was able to obtain a stable range of detection values matching the subgroups among participants of different genders, ages and stages of lung cancer, indicating that Luna's analysis was independent of gender and age, was able to accurately distinguish between lung adenocarcinoma patients and healthy people through plasma testing, and Luna's analysis identified early lung cancer patients and healthy people with higher accuracy and potential for early screening for lung cancer.
In July 2020,Far Gene also published a new scientific study from Fudan University, based on PanSeer, a multi-cancer screening technique based on methylation, which showed that PanSeer testing was able to detect trace ctDNA methylation signals for up to four years before clinical diagnosis, the first time in the world that pan-cancer early screening technology has been rigorously validated in large natural population queues.
It's also worth mentioning that at present,Far Gene is actively preparing FDA filings for its core product, Changles, which completed its second round of pre-trial trials in May this year, and is a blood-based, non-invased colorectal cancer. Early screening technology, with only a small amount of blood, can be based on the methylation characteristics of free tumor DNA (ctDNA) in the blood, using high-volume next-generation sequencing technology, early colorectal cancer and precancerote lesions (progressive adenoma) screening.
data show that Changles has a more significant advantage in sensitivity, specificity and convenience of early screening for colorectal cancer than existing fecal-based bowel cancer screening techniques.
Photo Source:Far Gene Website If the FDA approves the listing of clinical studies in the future, Changles will be the only non-invasive liquid biopsy technology based on blood test progressant adenoma and early bowel cancer, after the approved Act Sciences Cologuard and the country's first approved no-invasive early screening product for Nohui Health Bowel Cancer Changweiqing are based on fecal testing.
。